-
公开(公告)号：US08053429B2
公开(公告)日：2011-11-08
申请号：US12553196
申请日：2009-09-03
IPC分类号： A61K9/00
CPC分类号： A61K9/0002 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2846 , A61K47/12
摘要： The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
摘要翻译： 本发明涉及一种固体口服剂型，其包含与提高活性成分的生物利用度和/或吸收的增强剂组合的药物活性成分。 因此，固体口服剂型包括药物和增强剂，其中增强剂是中链脂肪酸酯，醚或盐或中链脂肪酸的衍生物，其优选在室温下为固体，并且其具有 碳链长度为6至20个碳原子。 优选地，固体口服剂型是控释剂型，例如延迟释放剂型。
-
公开(公告)号：US08323690B2
公开(公告)日：2012-12-04
申请号：US12768008
申请日：2010-04-27
CPC分类号： A61K9/0002 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2846 , A61K47/12
摘要： The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
-
公开(公告)号：US20100209499A1
公开(公告)日：2010-08-19
申请号：US12768008
申请日：2010-04-27
IPC分类号： A61K9/64 , A61K47/12 , A61K31/715 , A61K38/16 , A61K38/02 , A61K31/727 , A61K38/24 , A61K38/28 , A61K38/08 , A61K31/66 , A61K38/13 , A61K9/22 , A61K9/52 , A61P43/00
CPC分类号： A61K9/0002 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2846 , A61K47/12
摘要： The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
-
公开(公告)号：US20080275001A1
公开(公告)日：2008-11-06
申请号：US12172707
申请日：2008-07-14
IPC分类号： A61K31/727 , A61P7/02
CPC分类号： A61K9/0002 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2846 , A61K47/12
摘要： The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
摘要翻译： 本发明涉及一种固体口服剂型，其包含与提高活性成分的生物利用度和/或吸收的增强剂组合的药物活性成分。 因此，固体口服剂型包括药物和增强剂，其中增强剂是中链脂肪酸酯，醚或盐或中链脂肪酸的衍生物，其在室温下优选为固体，并且其具有 碳链长度为6至20个碳原子。 优选地，固体口服剂型是控释剂型，例如延迟释放剂型。
-
公开(公告)号：US08323689B2
公开(公告)日：2012-12-04
申请号：US12172707
申请日：2008-07-14
CPC分类号： A61K9/0002 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2846 , A61K47/12
摘要： The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
摘要翻译： 本发明涉及一种固体口服剂型，其包含与提高活性成分的生物利用度和/或吸收的增强剂组合的药物活性成分。 因此，固体口服剂型包括药物和增强剂，其中增强剂是中链脂肪酸酯，醚或盐或中链脂肪酸的衍生物，其优选在室温下为固体，并且其具有 碳链长度为6至20个碳原子。 优选地，固体口服剂型是控释剂型，例如延迟释放剂型。
-
公开(公告)号：US20100028421A1
公开(公告)日：2010-02-04
申请号：US12553196
申请日：2009-09-03
IPC分类号： A61K9/48 , A61K47/12 , A61K9/28 , A61K38/00 , A61K31/702 , A61K31/727 , A61K31/661 , A61K31/66 , A61K47/38 , A61K47/32 , A61K9/32
CPC分类号： A61K9/0002 , A61K9/1617 , A61K9/2013 , A61K9/2054 , A61K9/2846 , A61K47/12
摘要： The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
摘要翻译： 本发明涉及一种固体口服剂型，其包含与提高活性成分的生物利用度和/或吸收的增强剂组合的药物活性成分。 因此，固体口服剂型包括药物和增强剂，其中增强剂是中链脂肪酸酯，醚或盐或中链脂肪酸的衍生物，其优选在室温下为固体，并且其具有 碳链长度为6至20个碳原子。 优选地，固体口服剂型是控释剂型，例如延迟释放剂型。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.016 秒)
